What the trial was testing
The BE VIVID enrolled 567 patients with psoriasis. The study was sponsored by UCB Biopharma SRL and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
85% of patients achieved nearly clear skin in just 16 weeks compared to 50% on a standard psoriasis drug.
Lancet (London, England) · 2021 · NCT03370133
These findings — that nearly complete skin clearance versus 50% with standard treatment — were published in the Lancet (London, England) and represent the headline result of the study.
Researchers tracked outcomes across 567 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with psoriasis, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
This injection cleared severe psoriasis significantly faster and more completely than existing treatments. It's FDA-approved and represents an important new option if other psoriasis drugs haven't worked well enough for you. Talk to your doctor about whether this could be right for your situation.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open psoriasis trials
A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the efficacy and safety of IBI112 in the treatment of adolescent participants with moderate to severe plaque-type psoriasis.
Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease
The purpose of this research study is to determine the effectiveness of adding deucravacitinib to the participant's current Psoriatic Arthritis (PsA) treatment to see if it improves their symptoms and quality of life. This study is exploring a new treatment approach that may help improve control of psoriatic disease by targeting different parts of the disease process. By combining therapies that work together, the goal is to offer better symptom relief with fewer or more manageable side effects than some current treatments.